A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients.

Drug Category: Array
Conference Category: Array
Lead Author: Changchun D, O'Connor O, et al.
Published Date: 02/06/2013
Download Link: /wp-content/uploads/2019/03/ASCO2013Poster8575.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top